Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ARDS 36% Improvement Relative Risk c19early.org/d Saponaro et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 93 patients in Italy (March - May 2020) Lower ARDS with higher vitamin D levels (not stat. sig., p=0.43) Saponaro et al., Frontiers in Immunology, doi:10.3389/fimmu.2021.745713 Favors vitamin D Favors control
Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19?
Saponaro et al., Frontiers in Immunology, doi:10.3389/fimmu.2021.745713
Saponaro et al., Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19?, Frontiers in Immunology, doi:10.3389/fimmu.2021.745713
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 93 COVID-19 pneumonia patients in Italy, showing low vitamin D levels associated with severe ARDS, and significantly lower vitamin D levels for non-survivors.
risk of ARDS, 36.5% lower, RR 0.64, p = 0.43, high D levels (≥20ng/ml) 5 of 32 (15.6%), low D levels (<20ng/ml) 15 of 61 (24.6%), NNT 11, severe ARDS.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Saponaro et al., 24 Jan 2022, retrospective, Italy, peer-reviewed, 13 authors, study period March 2020 - May 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: ORIGINAL RESEARCH published: 24 January 2022 doi: 10.3389/fimmu.2021.745713 Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19? Federica Saponaro 1*, Maria Franzini 2, Chukwuma Okoye 3, Rachele Antognoli 3, Beatrice Campi 1, Marco Scalese 4, Tommaso Neri 1, Laura Carrozzi 1, Fabio Monzani 3, Riccardo Zucchi 1, Alessandro Celi 1, Aldo Paolicchi 2 and Alessandro Saba 1† on behalf of Pisa COVID-19 Study Group† 1 Department of Surgical, Medical, and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy, 3 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 4 Institute of Clinical Physiology, National Council of Research, Pisa, Italy 2 Edited by: Deirdre R. Coombe, Curtin University, Australia Reviewed by: Roi Gazit, Ben Gurion University of the Negev, Israel Peter Ramutis Kvietys, Alfaisal University, Saudi Arabia *Correspondence: Federica Saponaro federica.saponaro@unipi.it † Members are listed in the Acknowledgments section Specialty section: This article was submitted to Inflammation, a section of the journal Frontiers in Immunology Received: 13 August 2021 Accepted: 21 December 2021 Published: 24 January 2022 Citation: Saponaro F, Franzini M, Okoye C, Antognoli R, Campi B, Scalese M, Neri T, Carrozzi L, Monzani F, Zucchi R, Celi A, Paolicchi A and Saba A (2022) Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19? Front. Immunol. 12:745713. doi: 10.3389/fimmu.2021.745713 Background: Hypovitaminosis D has been suggested to play a possible role in coronavirus disease 2019 (COVID-19) infection. Methods: The aim of this study is to analyze the relationship between vitamin D status and a biochemical panel of inflammatory markers in a cohort of patients with COVID-19. A secondary endpoint was to evaluate the correlation between 25OHD levels and the severity of the disease. Ninety-three consecutive patients with COVID-19-related pneumonia were evaluated from March to May 2020 in two hospital units in Pisa, in whom biochemical inflammatory markers, 25OHD levels, P/F ratio at nadir during hospitalization, and complete clinical data were available. Results: Sixty-five percent of patients presented hypovitaminosis D (25OHD ≤ 20 ng/ml) and showed significantly higher IL-6 [20.8 (10.9–45.6) vs. 12.9 (8.7–21.1) pg/ml, p = 0.02], CRP [10.7 (4.2–19.2) vs. 5.9 (1.6–8.1) mg/dl, p = 0.003], TNF-a [8.9 (6.0–14.8) vs. 4.4 (1.5–10.6) pg/ml, p = 0.01], D-dimer [0.53 (0.25–0.72) vs. 0.22 (0.17–0.35) mg/l, p = 0.002], and IL-10 [3.7 (1.8–6.9) vs. 2.3 (0.5–5.8) pg/ml, p = 0.03]. A significant inverse correlation was found between 25OHD and all these markers, even adjusted for age and sex. Hypovitaminosis D was prevalent in patients with severe ARDS, compared with the other groups (75% vs. 68% vs. 55%, p < 0.001), and 25OHD levels were lower in nonsurvivor patients. Conclusions: The relationship between 25OHD levels and inflammatory markers suggests that vitamin D status needs to be taken into account in the management of these patients. If vitamin D is a marker of poor prognosis or a possible risk factor with beneficial effects from supplementation, this still needs to be elucidated. Keywords: COVID-19, SARS-CoV-2, hypovitaminosis D, vitamin D, cytokine storm Frontiers in Immunology |..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit